Clopidogrel 75 mg Tablets — Generic For Plavix — ScieGen

Name: $0.25 | Clopidogrel 75 mg Tablets --- Generic For Plavix --- ScieGen | Pill Pals
Brand: ScieGen
SKU: 50228-0124-05-1p
Price: 0.25 USD
Availability: InStock

$0.25 - or Auto-Reorder and Save 5%

Need A Prescription?See A Prescriber.

Clopidogrel 75 mg Tablets — Generic For Plavix — ScieGen is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.

Prescription Transfer Available

Need to transfer your prescription?

Request a prescription transfer and our pharmacy team will help coordinate the next step.

Request Prescription Transfer

Do you need this exact manufacturer? Check the box below.

I would like to include this drug in the Manufacturer Match™ Program. Pill Pals will try to keep me on this specific manufacturer for this drug.

Important: Manufacturer availability may vary due to shortages, recalls, wholesaler inventory, prescription requirements, and applicable laws.

Pill Pals will make a reasonable effort, but the same manufacturer cannot be guaranteed every time. Patients should not stop, change, or switch medications without speaking with their pharmacist or prescriber.

Select Delivery Options:

One Time Purchase
Auto-Reorder and Save 5%

SKU: 50228-0124-05-1p Categories: Pill Pass® - Save Money On Your Rx, Prescription Required Brand: ScieGen

Shop with Confidence at Pill Pals® - We're The EXPRESS Pharmacy

Secure checkout, SSL protection, and trusted shopping safeguards for Pill Pals® customers.

Description

Clopidogrel 75 mg Tablets is available by prescription only. Go ahead and place your purchase. After making payment, we will ensure that a valid prescription is received from your prescriber.

Drug Label Highlights

Source: This information is taken from the official DailyMed drug label page when available. It is provided for educational purposes and is not a substitute for pharmacist counseling, prescriber instructions, or the full official labeling.

These highlights do not include all the information needed to use CLOPIDOGREL TABLETS safely and effectively. See full prescribing information for CLOPIDOGREL TABLETS.

CLOPIDOGREL tablets, for oral use

Initial U.S. Approval: 1997

WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE

See full prescribing information for complete boxed warning.

Effectiveness of clopidogrel depends on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (

5.1,

12.3)

Tests are available to identify patients who are CYP2C19 poor metabolizers. (

12.5)

Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers. (

5.1)

Indications And Usage

Clopidogrel is a P2Y

12platelet inhibitor indicated for:

Acute coronary syndrome

For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. (

1.1)

For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. (

1.1)

Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. (

1.2)

Dosage And Administration

Acute coronary syndrome (

2.1)

Initiate clopidogrel with a single 300-mg oral loading dose and then continue at 75 mg once daily.

Initiate clopidogrel without a loading dose will delay establishment of an antiplatelet effect by several days.

Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose (

2.2)

Dosage Forms And Strengths

Tablets: 75 mg, 300 mg (

Contraindications

Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage (

4.1)

Hypersensitivity to clopidogrel or any component of the product (

4.2)

Warnings And Precautions

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (5.1)
Bleeding: Clopidogrel increases risk of bleeding. (5.2)
Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. (5.3)
Thrombotic thrombocytopenic purpura (TTP) has been reported. (5.4)
Cross-reactivity among thienopyridines has been reported. (5.5)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (5.1)
Bleeding: Clopidogrel increases risk of bleeding. (5.2)
Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. (5.3)
Thrombotic thrombocytopenic purpura (TTP) has been reported. (5.4)
Cross-reactivity among thienopyridines has been reported. (5.5)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole.

(5.1)

Bleeding: Clopidogrel increases risk of bleeding.

(5.2)

Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding.

(5.3)

Thrombotic thrombocytopenic purpura (TTP) has been reported.

(5.4)

Cross-reactivity among thienopyridines has been reported.

(5.5)

Adverse Reactions

Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. (

6.1)

To report SUSPECTED ADVERSE REACTIONS, contact ScieGen Pharmaceuticals Inc at 1-855-724-3436or FDA at 1-800-FDA-1088 or

www.fda.gov/medwatch.

Drug Interactions

CYP2C19 inducers: Increases levels of clopidogrel active metabolite and increases platelet inhibition. (

7.1)

Opioids: Decreased exposure to clopidogrel. Consider use of parenteral antiplatelet agent.

(7.3)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding.

(7.4,

7.5,

7.6)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (7.7)

Repaglinide (CYP2C8 substrates): Increases substrate plasma concentrations. (7.8)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 6/2023

View Full DailyMed Label View DailyMed PDF

DailyMed highlights last updated: 2026-06-24 22:23:28

Additional information

Size/Count	1 Count
Dose/Strength	75 mg
Form	Tablet

Medication Guide

Official DailyMed Drug Label Information

This product has a DailyMed drug label PDF from the National Library of Medicine.

View / Download PDF View on DailyMed

Source: DailyMed, National Library of Medicine
DailyMed Label: CLOPIDOGREL BISULFATE TABLET, FILM COATED [SCIEGEN PHARMACEUTICALS INC]
Matched NDC: 50228-124-05
Published Date: Oct 13, 2023

Medication Summary

Medication Summary: This section summarizes DailyMed drug label information to make the label easier to understand. It is not a substitute for the official label, pharmacist counseling, prescriber instructions, or medical advice.

Overview

Clopidogrel is a P2Y12 platelet inhibitor taken by mouth. It is used to help reduce the risk of heart attack and stroke in certain patients with acute coronary syndrome, recent heart attack, recent stroke, or established peripheral arterial disease.

For acute coronary syndrome, the label says treatment may start with a single 300-mg oral loading dose, then continue at 75 mg once daily. For recent heart attack, recent stroke, or established peripheral arterial disease, the usual dose is 75 mg once daily without a loading dose.

The label warns that clopidogrel can increase the risk of bleeding. It also warns that some patients may have reduced benefit if they have two loss-of-function CYP2C19 alleles or take certain medicines that affect CYP2C19.

Clopidogrel should not be used in patients with active pathological bleeding or hypersensitivity to clopidogrel or any component of the product.

Storage Information

store hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective. STORAGE AND HANDLING Clopidogrel tablets, USP 75 mg are available as pink colored, round shaped, biconvex, film coated tablets de-bossed on one side with SG and 124 on other side. Store at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature]. store clopidogrel tablets? Store clopidogrel tablets at 59°F to 86°F (15°C to 30°C).

Key Counseling Points

Take clopidogrel exactly as prescribed.
For acute coronary syndrome, the label describes starting with a 300-mg loading dose followed by 75 mg once daily.
For recent heart attack, recent stroke, or peripheral arterial disease, the label describes 75 mg once daily without a loading dose.
Tell your clinician if you have any history of bleeding or if you are taking medicines that increase bleeding risk.
Avoid taking omeprazole or esomeprazole with clopidogrel unless specifically directed, because the label says they reduce its antiplatelet activity.
Tell your clinician about all medicines you take, including NSAIDs, warfarin, SSRIs, SNRIs, opioids, other antiplatelet agents, and repaglinide.
Do not stop clopidogrel without medical guidance; the label warns that stopping it increases the risk of cardiovascular events.
Report signs of bleeding or bruising promptly, since bleeding is the most commonly reported adverse reaction.
Seek urgent medical attention for symptoms listed with thrombotic thrombocytopenic purpura, such as low platelets, anemia, neurologic findings, kidney problems, or fever.
Tell your clinician if you have been told you are a CYP2C19 poor metabolizer, since the label warns clopidogrel may work less well in those patients.

Helpful Patient Education

Clopidogrel tablets are a prescription P2Y12 platelet inhibitor used to help reduce the risk of heart attack and stroke in certain patients with acute coronary syndrome, recent heart attack, recent stroke, or established peripheral arterial disease. The DailyMed label also notes that clopidogrel is used with aspirin in some acute coronary syndrome settings.

This medicine has important safety information about bleeding risk, possible reduced effect in patients with certain CYP2C19 gene variants, and drug interactions, including with omeprazole or esomeprazole. Product information is based on the official DailyMed labeling for clopidogrel bisulfate tablets.

Medication Summary last generated: 2026-07-10 03:03:20

Clopidogrel 75 mg Tablets --- Generic For Plavix --- ScieGen may require patient-specific counseling based on your prescription, directions, allergies, medical history, and other medications.

This Medication Guide section is provided for general educational purposes only. It does not replace the official medication guide, patient information leaflet, counseling from your pharmacist, or medical advice from your prescriber.

Please read all information provided with your prescription. Contact Pill Pals Pharmacy or your prescriber with questions before using this medication.

Clopidogrel 75 mg Tablets — Generic For Plavix — ScieGen

Description